Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial

Adriaan A. Voors, Jean François Tamby, John G. Cleland, Michael Koren, Leslie B. Forgosh, Dinesh Gupta, Lars H. Lund, Albert Camacho, Ravi Karra, Henk P. Swart, Pierpaolo Pellicori, Frank Wagner, Ray E. Hershberger, Narayana Prasad, Robert Anderson, Anu Anto, Kaylyn Bell, Jay M. Edelberg, Liang Fang, Marcus HenzeCynthia Kelly, Gregory Kurio, Wanying Li, Kate Wells, Chun Yang, Sam L. Teichman, Carlos L. del Rio, Scott D. Solomon

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial'. Together they form a unique fingerprint.

Medicine & Life Sciences